We next used KP9-3, a C57B/L6-derived murine lung adenocarcinoma cell line driven by oncogenic Kras and Tp53 loss, to test the radiosensitization strategy in a syngeneic model (51). Here, KRAS is linked to lung adenocarcinoma.